Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | DRD4 | P21917 | 3/20 | 0.74 |
| ▸ | DRD1 | P21728 | 2/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.53 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431761 | 0.85 | DRD2 (0.57) | HRH4DRD2DRD4DRD1 | |
| SCHEMBL3696235 | 0.85 | DRD2 (0.60) | HRH4DRD2DRD4DRD1 | |
| SCHEMBL8203039 | 0.85 | DRD2 (1.00) | HRH4DRD2DRD4DRD1PAK1 | |
| SCHEMBL11636450 | 0.85 | DRD2 (0.59) | HRH4DRD2DRD4DRD1PAK1 | |
| SCHEMBL9174369 | 0.84 | DRD2 (0.58) | HRH4DRD2DRD4DRD1 | |
| SCHEMBL31266599 | 0.82 | HRH4 (0.56) | HRH4DRD2DRD4DRD1MAPK1 | |
| SCHEMBL6354527 | 0.82 | DRD2 (0.53) | HRH4DRD2DRD4DRD1MAPK1 | |
| SCHEMBL7835099 | 0.79 | DRD2 (0.60) | HRH4DRD2DRD4DRD1MAPK1 | |
| SCHEMBL10620991 | 0.77 | HRH4 (0.56) | HRH4DRD2DRD4DRD1MAPK1 | |
| Perlapine SCHEMBL114768 | 0.77 | HRH4 (1.00) | HRH4DRD2DRD4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
| US-3962248-A | PROCESS FOR MAKING 11-PIPERAZINO-DIAZEPINES, OXAZEPINES, THIAZEPINES AND AZEPINES | SANDOZ, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HRH4 870/4885DRD2 242/4885DRD4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.